Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 248,030,720
  • Shares Outstanding, K 2,529,635
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • EBIT $ 14,160 M
  • EBITDA $ 18,032 M
  • 60-Month Beta 0.39
  • Price/Sales 4.19
  • Price/Cash Flow 32.71
  • Price/Book 5.66

Options Overview Details

View History
  • Implied Volatility 23.82% ( -1.44%)
  • Historical Volatility 22.84%
  • IV Percentile 82%
  • IV Rank 57.30%
  • IV High 30.32% on 10/28/24
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.69
  • Today's Volume 29,431
  • Volume Avg (30-Day) 25,165
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 427,847
  • Open Int (30-Day) 416,076

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.80
  • Number of Estimates 6
  • High Estimate 1.90
  • Low Estimate 1.63
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +5,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.95 +1.13%
on 11/21/24
105.07 -6.68%
on 12/09/24
+0.61 (+0.63%)
since 11/20/24
3-Month
94.48 +3.78%
on 11/15/24
118.16 -17.02%
on 09/23/24
-19.12 (-16.32%)
since 09/20/24
52-Week
94.48 +3.78%
on 11/15/24
134.63 -27.17%
on 06/25/24
-7.31 (-6.94%)
since 12/20/23

Most Recent Stories

More News
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (NYSE: MRK) .

VKTX : 42.25 (+1.83%)
MRK : 98.05 (-1.48%)
Why Viking Therapeutics Tumbled by More Than 10% This Week

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (NASDAQ: VKTX) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence,...

VKTX : 42.25 (+1.83%)
NVO : 85.00 (-17.83%)
MRK : 98.05 (-1.48%)
LLY : 767.76 (+1.35%)
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has...

MRK : 98.05 (-1.48%)
GILD : 92.57 (+1.62%)
GSK : 33.60 (+0.51%)
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

This week, Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary...

MRK : 98.05 (-1.48%)
TEVA : 22.09 (+3.66%)
ABBV : 175.58 (+2.37%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks

Collecting dividend income on a recurring basis can help strengthen your financial position and be a way for you to be less dependent on other sources of cash flow. The one downside is that many dividend...

T : 22.75 (+0.80%)
CVX : 142.85 (+1.20%)
MRK : 98.05 (-1.48%)
3 Stocks That Could Turn $1,000 into $5,000 by 2030

A five-bagger in only five years? Any investor would love to buy such a stock. Fortunes can be made quickly with those kinds of turbocharged performers.

GOOGL : 191.41 (+1.54%)
GOOG : 192.96 (+1.72%)
TSLA : 421.06 (-3.46%)
MRK : 98.05 (-1.48%)
SMMT : 17.87 (-2.88%)
WRD : 14.70 (-2.46%)
MRNA : 39.39 (-0.43%)
UBER : 60.73 (+0.86%)
Viking Therapeutics Stock Slides After Merck Strikes GLP-1 Deal With Chinese Biopharma, Retail Unperturbed

Viking’s own promising oral GLP-1 candidate, VK2735, is currently being studied for obesity and other metabolic conditions.

VKTX : 42.25 (+1.83%)
MRK : 98.05 (-1.48%)
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance

Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants...

AZN : 65.35 (+1.41%)
MRK : 98.05 (-1.48%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over

It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare...

ALK : 66.02 (+1.62%)
MRK : 98.05 (-1.48%)
JNJ : 144.47 (+0.62%)
NKE : 76.94 (-0.21%)
$DOWI : 42,840.26 (+1.18%)
AMGN : 263.38 (+0.84%)
BA : 177.35 (+0.18%)
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy”

These two biotech companies look poised to deliver in the coming year.

PCVX : 86.53 (+0.37%)
$SPX : 5,930.85 (+1.09%)
MRK : 98.05 (-1.48%)
AIT : 240.58 (-1.18%)
PFE : 26.36 (+2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 100.97
2nd Resistance Point 100.32
1st Resistance Point 99.19
Last Price 98.05
1st Support Level 97.41
2nd Support Level 96.76
3rd Support Level 95.63

See More

52-Week High 134.63
Fibonacci 61.8% 119.29
Fibonacci 50% 114.56
Fibonacci 38.2% 109.82
Last Price 98.05
52-Week Low 94.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar